Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02073097 · ClinicalTrials.gov registry record · Phase 1
Carfilzomib, Rituximab, and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Lymphoma
A Phase 1 study, sponsored by Case Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT02073097 is a Phase 1 study that has completed, run by Case Comprehensive Cancer Center. The registered enrollment target is 48 participants.
The verdict
NCT02073097, a Phase 1 study, has completed, sponsored by Case Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
This phase I/II trial studies the side effects and best dose of carfilzomib when given together with rituximab and combination chemotherapy and to see how well they work in treating patients with diffuse large B-cell lymphoma. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as rituximab, can block cancer growth by finding cancer cells and helping kill them. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. It is not known if carfilzomib in combination with R-CHOP is better or worse than R-CHOP alone in treating patients with diffuse large b-cell lymphoma.
Interventions
- DRUG Cyclophosphamide
- BIOLOGICAL Rituximab
- DRUG Carfilzomib
- DRUG Doxorubicin hydrochloride
- DRUG Vincristine sulfate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2015-01-28 |
| Est. Completion | 2023-06-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02073097
The ClinicalTrials.gov registry entry for NCT02073097 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT02073097 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02073097 about?
NCT02073097 is a clinical study titled "Carfilzomib, Rituximab, and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Lymphoma". This phase I/II trial studies the side effects and best dose of carfilzomib when given together with rituximab and combination chemotherapy and to see how well they work in treating patients with diffuse large B-cell lymphoma. Carfilzomib may stop the growth of cancer cells by blocking some of the e...
What is the current status of trial NCT02073097?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2015-01-28. Estimated completion is 2023-06-29.
What interventions are being tested in trial NCT02073097?
The interventions under investigation include: Cyclophosphamide (DRUG), Rituximab (BIOLOGICAL), Carfilzomib (DRUG), Doxorubicin hydrochloride (DRUG), Vincristine sulfate (DRUG).
Who is sponsoring clinical trial NCT02073097?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.